Cidara Therapeutics (CDTX) Rockets 722% in 2025 on Merck $9.2-Billion Merger

Group 1 - Cidara Therapeutics Inc. is projected to be a top performer with a 721.76% increase in 2025, driven by a merger with Merck valued at $9.2 billion [1] - The merger agreement includes Merck's subsidiary acquiring Cidara's shares at $221.50 each, representing a 108% premium over Cidara's closing price of $105.99 prior to the announcement [1] - The acquisition follows Cidara receiving a fast track designation from the FDA for its drug candidate CD388, aimed at preventing influenza in high-risk individuals [2] Group 2 - CD388 is currently in a Phase 3 study involving 6,000 participants in the US and UK, targeting individuals at higher risk of influenza complications [2] - Merck's acquisition is expected to enhance its respiratory portfolio, addressing the significant global health threat posed by influenza, particularly for older adults and immunocompromised individuals [2] - The merger is anticipated to be completed in the first quarter of 2026, pending regulatory and shareholder approvals [2]